Exact Sciences Corporation (EXAS) Rating Reiterated by Robert W. Baird

Robert W. Baird reissued their buy rating on shares of Exact Sciences Corporation (NASDAQ:EXAS) in a report issued on Friday. They currently have a $49.00 price objective on the medical research company’s stock.

A number of other analysts have also commented on the company. Vetr lowered Exact Sciences Corporation from a hold rating to a sell rating and set a $34.70 price target on the stock. in a research note on Wednesday, July 12th. BidaskClub raised Exact Sciences Corporation from a buy rating to a strong-buy rating in a research note on Friday, August 25th. Canaccord Genuity reissued a buy rating and set a $45.00 price target on shares of Exact Sciences Corporation in a research note on Thursday, September 7th. Benchmark Co. set a $50.00 price target on Exact Sciences Corporation and gave the company a buy rating in a research note on Friday, July 7th. Finally, BTIG Research reissued a buy rating and set a $45.00 price target (up from $35.00) on shares of Exact Sciences Corporation in a research note on Monday, July 17th. Five analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. Exact Sciences Corporation currently has an average rating of Buy and a consensus price target of $43.71.

Exact Sciences Corporation (NASDAQ:EXAS) opened at 47.99 on Friday. Exact Sciences Corporation has a 12-month low of $13.05 and a 12-month high of $50.65. The company has a 50 day moving average price of $43.69 and a 200-day moving average price of $35.56. The company’s market capitalization is $5.72 billion.

Exact Sciences Corporation (NASDAQ:EXAS) last released its quarterly earnings data on Tuesday, July 25th. The medical research company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.10. The business had revenue of $57.65 million for the quarter, compared to analyst estimates of $47.73 million. Exact Sciences Corporation had a negative return on equity of 36.36% and a negative net margin of 83.08%. On average, analysts anticipate that Exact Sciences Corporation will post ($1.18) EPS for the current year.

WARNING: This piece of content was reported by BBNS and is owned by of BBNS. If you are reading this piece of content on another website, it was stolen and reposted in violation of United States and international copyright & trademark laws. The correct version of this piece of content can be read at https://baseballnewssource.com/markets/exact-sciences-corporation-exas-rating-reiterated-by-robert-w-baird/1703057.html.

In other Exact Sciences Corporation news, CFO Jeffrey Thomas Elliott sold 5,846 shares of Exact Sciences Corporation stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $39.41, for a total value of $230,390.86. Following the completion of the sale, the chief financial officer now directly owns 19,861 shares in the company, valued at $782,722.01. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Thomas D. Carey bought 2,500 shares of the stock in a transaction on Thursday, August 17th. The stock was acquired at an average price of $37.71 per share, with a total value of $94,275.00. Following the completion of the acquisition, the director now owns 60,858 shares of the company’s stock, valued at approximately $2,294,955.18. The disclosure for this purchase can be found here. Insiders have sold 237,444 shares of company stock valued at $10,412,421 over the last 90 days. 4.00% of the stock is owned by corporate insiders.

A number of hedge funds have recently modified their holdings of the business. Advisor Group Inc. increased its holdings in Exact Sciences Corporation by 0.8% in the second quarter. Advisor Group Inc. now owns 7,866 shares of the medical research company’s stock worth $270,000 after purchasing an additional 65 shares in the last quarter. Stifel Financial Corp increased its holdings in Exact Sciences Corporation by 1.5% in the first quarter. Stifel Financial Corp now owns 21,475 shares of the medical research company’s stock worth $506,000 after purchasing an additional 310 shares in the last quarter. Prudential Financial Inc. increased its holdings in Exact Sciences Corporation by 3.0% in the first quarter. Prudential Financial Inc. now owns 11,141 shares of the medical research company’s stock worth $263,000 after purchasing an additional 320 shares in the last quarter. Ameritas Investment Partners Inc. increased its holdings in Exact Sciences Corporation by 5.6% in the second quarter. Ameritas Investment Partners Inc. now owns 9,640 shares of the medical research company’s stock worth $341,000 after purchasing an additional 511 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. increased its holdings in Exact Sciences Corporation by 17.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 4,072 shares of the medical research company’s stock worth $144,000 after purchasing an additional 600 shares in the last quarter. Institutional investors and hedge funds own 85.22% of the company’s stock.

About Exact Sciences Corporation

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Analyst Recommendations for Exact Sciences Corporation (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related companies with our FREE daily email newsletter.

 


Latest News

Justin Turner Joining Postseason Legends
Justin Turner Joining Postseason Legends
PED Use Cost Alex Rodriguez Millions and His Reputation
PED Use Cost Alex Rodriguez Millions and His Reputation
Yankees to Send Masahiro Tanaka Against Astros in Game 1
Yankees to Send Masahiro Tanaka Against Astros in Game 1
Red Sox Waste Little Time in Firing John Farrell
Red Sox Waste Little Time in Firing John Farrell
Washington Nationals Sans Strasburg for Game 4 at Wrigley
Washington Nationals Sans Strasburg for Game 4 at Wrigley
Red Sox Beat Houston Sunday to Avoid Elimination
Red Sox Beat Houston Sunday to Avoid Elimination


Leave a Reply

 
© 2006-2017 BBNS.